Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
LB Pharmaceuticals Q2 FY26 net loss widens to $51.6 million

LB Pharmaceuticals Q2 FY26 net loss widens to $51.6 million

ReutersReuters2026/08/11 12:02
  • LB Pharmaceuticals posted a Q2 net loss of USD 51.6 million, widening from USD 4.9 million a year earlier.
  • RD costs climbed to USD 44.1 million from USD 2.4 million, driven mainly by higher Phase 3 LB-102 schizophrenia trial spending.
  • GA expense rose to USD 9.8 million from USD 2.4 million, on higher stock-based compensation, professional fees, and headcount.
  • Cash, equivalents, and marketable securities totaled USD 327.8 million at June 30, excluding a July USD 150 million private placement; runway projected beyond Q2 2029.
  • Phase 3 NOVA-2 LB-102 schizophrenia topline data is expected in H1 2027, with a pre-NDA meeting targeted for H2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110800PRIMZONEFULLFEED9807148) on August 11, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!